dacarbazine has been researched along with fotemustine in 80 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (45.00) | 18.2507 |
| 2000's | 26 (32.50) | 29.6817 |
| 2010's | 18 (22.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I | 1 |
| Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O | 1 |
| Boaziz, C | 1 |
| Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
| Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
| Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O | 1 |
| Aamdal, S; Bohman, T; D'Incalci, M; Gerard, B | 1 |
| Lee, SM; Margison, GP; Thatcher, N | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I | 1 |
| Boaziz, C; Breau, JL; Israël, L; Morere, JF | 1 |
| Avril, MF; Bonneterre, J; Bugat, R; Cupissol, D; Delaunay, M; Fumoleua, P; Grosshans, E; Israel, L; Kerbrat, P; Namer, M | 1 |
| Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G | 1 |
| Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
| A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A | 1 |
| Cooper, DP; Lee, SM; Margison, GP; O'Connor, PJ; Thatcher, N | 1 |
| Bureau, B; Célérier, P; Dreno, B; Litoux, P | 1 |
| Aschele, C; Bolli, E; Guglielmi, A; Mori, A; Nobile, MT; Rosso, R; Sobrero, A; Tixi, L | 1 |
| Chaitchik, S; Merimsky, O | 1 |
| Aliaga, A; Bizzari, JP; Cour, V; Lopez Lopez, JJ; Oliver, V; Perez, E; Ponchon, A | 1 |
| Dougal, M; Lee, SM; Margison, GP; Thatcher, N | 1 |
| Aamdal, S; Bizzari, JP; D'Incalci, M; Gerard, B; Lee, SM; Leyvraz, S; Lucas, C | 1 |
| Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA | 1 |
| Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M | 1 |
| Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
| Anderson, CM; Buzaid, AC; Legha, SS | 1 |
| Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F | 1 |
| Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG | 1 |
| Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
| Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S | 1 |
| Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F | 1 |
| Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K | 1 |
| Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D | 1 |
| Comella, P; Daponte, A | 1 |
| Gademann, G; Gollnick, H; Ulrich, J | 1 |
| Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M | 1 |
| Dieckmann, K; Fazeny-Dörner, B; Hainfellner, J; Marosi, C; Piribauer, M; Rössler, K; Ungersböck, K; Veitl, M; Wenzel, C | 1 |
| Dréno, B; Wallon-Dumont, G | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR | 1 |
| Dieckmann, K; Fazeny-Dörner, B; Marosi, C; Piribauer, M; Rössler, K; Ungersböck, K; Veitl, M; Wenzel, C | 1 |
| Baumgartner, G; Budinsky, A; Czech, T; Dieckmann, K; Fazeny-Dörner, B; Gyries, A; Killer, M; Marosi, C; Muhm, M; Piribauer, M; Prayer, D; Rössler, K; Ungersböck, K; Veitl, M | 1 |
| Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M | 1 |
| Eigentler, TK; Garbe, C | 1 |
| Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F | 1 |
| Fazeny-Dörner, B; Mader, RM; Marosi, C; Piribauer, M; Rizovski, B; Stögermaier, B | 1 |
| Christmann, M; Garcia Boy, R; Kaina, B; Mühlhausen, U; Piee-Staffa, A; Rösch, F; Schirrmacher, R | 1 |
| Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF | 1 |
| Grange, JD; Kodjikian, L; Rivoire, M | 1 |
| Fabian, K; Kaina, B; Thacker, J; Tsaryk, R | 1 |
| Audra, P; Cartalat-Carel, S; Colin, P; Ducray, F; Gaucherand, P; Honnorat, J; Mahla, K; Pelissou-Guyotat, I; Trouillas, P | 1 |
| Cuttone, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Todorović, DV; Valastro, LM | 1 |
| Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Camlica, H; Tas, F; Topuz, E | 1 |
| Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S | 1 |
| Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ | 1 |
| Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A | 1 |
| Cuttone, G; Iannolo, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Valastro, LM; Zakula, JJ | 1 |
| de Wind, N; Güvercin, F; Kaina, B; Roos, WP; Tsaalbi-Shtylik, A; Tsaryk, R | 1 |
| Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B | 1 |
| Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M | 1 |
| Di Giacomo, AM; Maio, M; Margolin, KA | 1 |
| Albanese, A; Anile, C; Balducci, M; Chiesa, S; D'Agostino, GR; De Bari, B; De Rose, F; Diletto, B; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Micciche', F; Morganti, AG; Valentini, V | 1 |
| Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
| Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M | 1 |
| Bonizzoni, E; Detti, B; Fabrini, MG; Lolli, I; Paccapelo, A; Perrone, F; Perrone, T; Santoni, M; Savio, G; Scoccianti, S; Silvano, G | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
| Aprea, P; Ascierto, PA; Botti, G; Caracò, C; Cavalcanti, E; Comella, G; Cossu, A; Daponte, A; Gallo, C; Grimaldi, AM; Lastoria, S; Maiorino, L; Massidda, B; Mozzillo, N; Palmieri, G; Petrillo, A; Signoriello, S; Simeone, E | 1 |
| Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
| Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S | 1 |
| Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E; Tosoni, A | 1 |
| Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V | 1 |
| Buonerba, C; Cerbone, L; Cordua, N; De Placido, S; Di Lorenzo, G; Lamberti, G; Marinelli, A; Peluso, G | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
12 review(s) available for dacarbazine and fotemustine
| Article | Year |
|---|---|
[Contribution of a new nitrosourea compound: fotemustine].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine | 1991 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States | 2010 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Temozolomide; Vincristine | 2016 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
26 trial(s) available for dacarbazine and fotemustine
| Article | Year |
|---|---|
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Remission Induction | 1992 |
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1990 |
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome | 1994 |
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia | 1993 |
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine | 1995 |
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Rate | 1997 |
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms | 1997 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 1999 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Survival Rate | 2003 |
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2003 |
Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Survival Rate | 2003 |
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis | 2004 |
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Sex Factors | 2004 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Salvage Therapy; Temozolomide | 2008 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2008 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Prospective Studies; Temozolomide | 2008 |
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult | 2008 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Temozolomide | 2009 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Odds Ratio; Organophosphorus Compounds; Temozolomide; Time Factors; Tomography, X-Ray Computed | 2011 |
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Analysis | 2013 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Thrombocytopenia | 2018 |
43 other study(ies) available for dacarbazine and fotemustine
| Article | Year |
|---|---|
Cerebral metastatic melanoma: correlation between clinical and CT findings.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed | 1992 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pneumonia | 1992 |
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
Topics: Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1991 |
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1991 |
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1990 |
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured | 1990 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxyguanosine; DNA; Female; Humans; Leukocytes; Lymphocytes; Male; Middle Aged; Nitrosourea Compounds; Nucleotidyltransferases; Organophosphorus Compounds | 1994 |
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1993 |
Dacarbazine and fotemustine in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1993 |
Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1993 |
Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction | 1993 |
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Leukocytes, Mononuclear; Melanoma; Methyltransferases; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1993 |
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome | 1993 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
Primary malignant melanoma of the vagina: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Vaginal Neoplasms | 1998 |
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1998 |
Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1999 |
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis | 1999 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy Dosage; Survival Analysis; Time Factors; Tomography, X-Ray Computed | 2003 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Epilepsies, Partial; Etoposide; Female; Follow-Up Studies; Humans; Life Tables; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Oligodendroglioma; Organophosphorus Compounds; Procarbazine; Prognosis; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis; Technetium Tc 99m Sestamibi; Temozolomide; Treatment Outcome; Vincristine | 2004 |
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.
Topics: Antineoplastic Agents; Cell Death; Dacarbazine; Enzyme Inhibitors; Glucose; HeLa Cells; Humans; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 2004 |
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2004 |
Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Follow-Up Studies; Hepatectomy; Humans; Injections, Intra-Arterial; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Time Factors; Uveal Neoplasms | 2005 |
Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cisplatin; Cyclophosphamide; Dacarbazine; DNA-Binding Proteins; Humans; Methylnitronitrosoguanidine; Mitomycin; Mutagens; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamazepine; Carmustine; Case Management; Cesarean Section; Chemotherapy, Adjuvant; Cranial Irradiation; Craniotomy; Dacarbazine; Female; Frontal Lobe; Glioblastoma; Humans; Infant, Newborn; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Paresis; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Temozolomide; Temporal Lobe | 2006 |
Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy | 2007 |
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Protons | 2009 |
The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Dacarbazine; DNA Damage; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Screening Assays, Antitumor; Flow Cytometry; Mice; Mice, Knockout; Microscopy, Fluorescence; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2009 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2010 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Temozolomide | 2012 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Risk Factors; Temozolomide; Time Factors; Treatment Failure | 2012 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Diphosphonates; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Male; Mice; Mice, Inbred Strains; Nanoparticles; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2016 |